Login
Home
EMN
About EMN
EMN membership
Latest research
Minimal Residual Disease in Multiple Myeloma
Collaborate groups
Guidelines
Investigators
Investigators expertise list
Policies & templates
Privacy & cookies
Trials
News
Publications
Home
EMN
About EMN
EMN membership
Latest research
Minimal Residual Disease in Multiple Myeloma
Collaborate groups
Guidelines
Investigators
Investigators expertise list
Policies & templates
Privacy & cookies
Trials
News
Publications
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
Abstract:
[Not available, this was published as a letter to the editor]